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ABSTRACT
Rationale Newborn screening (NBS) for cystic ﬁbrosis
(CF) allows early intervention. Design of randomised
controlled trials (RCT) is currently impeded by uncertainty
regarding evolution of lung function, an important trial
end point in such infants.
Objective To assess changes in pulmonary function
during the ﬁrst year of life in CF NBS infants.
Methods Observational longitudinal study. CF NBS
infants and healthy controls were recruited between
2009 and 2011. Lung Clearance Index (LCI),
plethysmographic lung volume (plethysmographic
functional residual capacity (FRCpleth)) and forced expired
volume (FEV0.5) were measured at 3 months and 1 year
of age.
Main results Paired measurements were obtained
from 72 CF infants and 44 controls. At 3 months, CF
infants had signiﬁcantly worse lung function for all tests.
FEV0.5 improved signiﬁcantly (0.59 (95% CI 0.18 to
0.99) z-scores; p<0.01) in CF infants between 3 months
and 1 year, and by 1 year, FEV0.5 was only 0.52 (0.89
to 0.15) z-scores less than in controls. LCI and FRCpleth
remained stable throughout the ﬁrst year of life, being
on average 0.8 z-scores higher in infants with CF.
Pulmonary function at 1 year was predicted by that at
3 months. Among the 45 CF infants with entirely normal
LCI and FEV0.5 at 3 months, 80% remained so at 1 year,
while 74% of those with early abnormalities remained
abnormal at 1 year.
Conclusions This is the ﬁrst study reporting
improvements in FEV0.5 over time in stable NBS CF
infants treated with standard therapy. Milder changes in
lung function occurred by 1 year than previously
reported. Lung function at 3 months predicts a high-risk
group, who should be considered for intensiﬁcation of
treatment and enrolment into RCTs.
INTRODUCTION
The major cause of morbidity and mortality in cystic
ﬁbrosis (CF) is pulmonary disease. Until recently,
treatment has been targeted at the downstream con-
sequences of CFTR dysfunction, such as bronchial
infection, inﬂammation and mucus retention. A
recent paradigm shift has, however, led to develop-
ment of genotype class-speciﬁc therapies, such as
PTC124 to over-ride premature stop codons
1 2 and
VX-770 for the class 3 mutation G551D.3 4 It seems
likely that these novel therapies will be most effect-
ive in early stage disease, before irreversible airway
damage has developed. It is therefore essential to
understand the evolution of lung function in
newborn screened (NBS) CF infants given standard
treatment, in order to determine optimal trial end-
points and adequately power intervention studies.
CF infants diagnosed clinically have airﬂow
obstruction at diagnosis, even in the absence of
respiratory symptoms, signs or history of infection,5
with no improvement in pulmonary function over
the ensuing years despite specialist treatment.6–8 CF
NBS has been introduced in the hope that earlier
diagnosis will lead to improved outcomes. Previous
longitudinal studies investigating lung function in
NBS CF infants reported progressive decline in the
early years, despite specialist treatment.9 10
Following recent universal introduction of screen-
ing throughout the UK, we recruited a cohort of
NBS infants with CF and healthy controls between
2009 and 2011. Disappointingly, only 56% of those
with CF had normal pulmonary function tests (PFT)
when assessed at 3 months.11 The current manu-
script describes follow-up PFTs at 1 year for this
cohort. Our primary hypothesis was that lung func-
tion would deteriorate further between 3 months
and 1 year of age. We also aimed to investigate the
determinants of lung function at 1 year, and to
Key messages
What is the key question?
▸ Newborn screened cystic ﬁbrosis (CF) infants
have abnormal lung function by 3 months of
age; how does this change during the ﬁrst year
of life?
What is the bottom line?
▸ Lung function remained stable or improved in
newborn screened CF infants during the ﬁrst
year of life; deﬁcits at 1 year were considerably
smaller than previously documented in either
screened or clinically diagnosed infants.
Why read on?
▸ This study, the largest of its kind and the only
one with contemporaneous healthy controls,
describes early lung development in newborn
screened infants with CF; these data will inform
the design of interventional trials in these
children.
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collect data to assess feasibility of recruiting NBS CF infants to
invasive studies12 and inform future power calculations.
METHODS
NBS CF infants born between January 2009 and July 2011 who
were referred to the six specialist CF centres in the London CF
Collaboration (LCFC) were eligible for recruitment.11 Healthy
controls were recruited contemporaneously from Homerton
University Hospital, East London. Infants were ineligible if born
<36 weeks gestation or had coexisting congenital abnormalities
(see online supplementary data). The study was approved by the
North Thames Multi-Centre Research Ethics Committee (#09/
HO71/314). Informed written parental consent was obtained.
Participating centres prospectively completed Case Record
Forms (CRF) at diagnosis and each subsequent clinic visit (see
online supplementary data). CF infants were started on multivi-
tamins and vitamin E, pancreatic enzyme replacement therapy
where appropriate and, in accord with UK CF Trust guidelines,
prophylactic ﬂucloxacillin, according to a standardised treatment
protocol (see online supplementary data).
Infant PFTs
All infants were tested at Great Ormond Street Hospital/UCL
Institute of Child Health at around 3 months and 1 year post-
natal age. Infants were free of respiratory illness for at least
3 weeks before PFTs. Infants were weighed and examined prior
to administering chloral hydrate orally or rectally (60–100 mg/
kg). Weight and crown-heel length were expressed as z-scores to
adjust for age and sex.13 Heart rate and SpO2 were monitored
continuously throughout testing. Infant urine or maternal saliva
samples were collected for cotinine assay to validate maternal
report of smoking. PFTs were undertaken according to inter-
national guidelines.14 15 Lung Clearance Index (LCI), a measure
of ventilation inhomogeneity was measured by multiple breath
washout (MBW), using mass spectrometry and customised soft-
ware.16 Plethysmographic Functional Residual Capacity
(FRCpleth) and forced expired volumes (FEV0.5) and ﬂows
(FEF75) from an inﬂation pressure of 30 cm H2O using the
raised volume technique were measured using the Jaeger
BabyBody device (CareFusion, San Diego, USA; V.4.65).15 PFT
results were electronically exported to a research database
(Re-Base software, Re-Base, UK), which contained all relevant
demographic and clinical details. PFT results were expressed as
z-scores to adjust for body size, sex and age, using reference
equations derived from healthy infants studied with identical
equipment and protocols.11 17–19 Abnormal PFTs were deﬁned
as results outside the 95% limits of normal: that is, >1.96
z-scores (>97.5th centile) for LCI and FRCpleth or <−1.96
z-scores (<2.5th centile) for FEV0.5. Results were reported to
the physicians responsible for the clinical care of each child, and
subsequently discussed with parents.
Statistical analysis
Data were inspected for distribution and calculation of descrip-
tive statistics (PASW Statistics V.18, Chicago, Illinois, USA).
Signiﬁcance was taken as p<0.05. Lung function results at
3 months, at 1 year and changes between 3 months and 1 year
were compared between groups using Student t-test.
Multivariable linear regressions were used to investigate how
lung function variables at 1 year, and change in lung function
between 3 months and 1 year, varied according to potential
determinants (background characteristics, clinical symptoms,
antibiotic treatment and microbiological results, see online sup-
plementary data for details). Model estimates and differences
between groups are presented with 95% CIs. Multiple imputa-
tions were used to impute values for any failed PFTs at
3 months (see online supplementary data). Taking into account
three primary outcomes (LCI, FRCpleth and FEV0.5), a sample
size of 72 infants with CF and 44 controls at 1 year (equivalent
to 53/group if equal groups) allows detection of differences
between groups equivalent to 0.66 z-scores at the 5% signiﬁ-
cance level with 84% power.20–22
RESULTS
The screening, recruitment and follow-up of subjects are
shown in ﬁgure 1. Paired measurements at 3 months and
1 year were obtained from 72 of 101 CF NBS infants, (90%
of those tested at ∼3 months of age). Inspection of CRFs and
regular communication with consultants revealed excellent
adherence to treatment protocols. Details of additional treat-
ment are provided in the online supplementary data. Paired
measurements were obtained from 44 contemporaneous con-
trols (81% of those tested at 3 months). CF infants were born
slightly earlier with lower birth weight than controls, but
background characteristics were otherwise similar (table 1).
There was no difference between groups regarding change in
weight between birth and ﬁrst PFTs at ∼3 months (mean dif-
ference CF-controls: −0.14 (95% CI −0.56 to 0.29) weight
z-scores).
For CF NBS infants, the median (IQR) age at diagnosis was
3.6 (3.0–4.4) weeks with 7 (10%) infants presenting with meco-
nium ileus. Since inclusion of these infants did not affect the
results (data not shown), they were included in the analysis. At
1 year PFTs, cough-swab cultures had been positive on at least
one occasion for Pseudomonas aeruginosa in 25 (35%), and for
other signiﬁcant bacteria in 17 (24%).
Anthropometry and lung function results
Comparison between infants with CF and healthy controls
Success in obtaining technically satisfactory PFTs were similar
between groups, but varied by age and outcome, being lowest
for FRCpleth at 3 months (76%) and highest for LCI (≥93%
on both occasions; ﬁgure 1 and see online supplementary
table E1). At 3 months, CF infants had signiﬁcantly lower
weight, height and body mass index (BMI); higher LCI and
FRCpleth; and lower FEV0.5, forced vital capacity (FVC) and
FEF75 compared with controls (table 2). Signiﬁcant increases
in z-scores for somatic growth were observed in both groups
between 3 and 12 months, but changes were signiﬁcantly
greater in CF infants, such that there were no between-group
differences by 1 year. All PFT results remained stable in
healthy infants during the ﬁrst year of life, as did LCI,
FRCpleth and FVC in those with CF. However, FEV0.5 and
FEF75 z-scores improved between test occasions in CF infants
(table 2, see online supplementary ﬁgure E1): differences in
FEF75 no longer being signiﬁcant by 1 year when compared
with controls. Although not one of the selected primary out-
comes, there was a signiﬁcant increase in gas trapping (as
reﬂected by ΔFRC, ie, the within-subject difference in FRC
assessed using plethysmography and MBW) in CF infants
during the ﬁrst year of life (table 2).
Determinants of lung function at 1 year
On linear univariable analysis, LCI, FRCpleth and FEV0.5
z-scores at 1 year were signiﬁcantly associated with CF status
and 3 months PFT (see online supplementary table E3). Using
multivariable linear regression, signiﬁcant determinants of
1 year LCI z-score were: CF status (regression coefﬁcient (95%
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CI) 0.48 (0.04 to 0.93)), 3 month LCI (0.24 (0.07 to 0.41) per
unit z-score), history of clinician-diagnosed wheeze (0.59 (0.05
to 1.12)) and change in weight z-score between birth and ﬁrst
PFT (−0.18 (−0.35 to −0.01) per unit z-score). For 1 year
FRCpleth z-score, determinants were: 3 months FRCpleth (0.43
(0.27 to 0.59) per unit z-score), history of PsA infection (0.71
(0.24 to 1.17)) and change in weight z-score between 3 and
12 months (−0.20 (−0.41 to 0.0) per unit z-score change),
whereas 1 year FEV0.5 z-score was only signiﬁcantly associated
with 3 months FEV0.5 on multivariable analysis (−0.18 (−0.35
to −0.01) per unit z-score).
Relationship between PFT results at 3 months and 1 year
At 3 months of age, LCI, FRCpleth and FEV0.5 were abnormal in
17% (12/71), 16% (9/57) and 26% (18/68) of CF infants,
respectively. By 1 year, the percentage with abnormal FEV0.5
had decreased to 9% (6/69) (mean difference (95% CI) −18%
(−30% to −5%)) whereas those with abnormal LCI (18% (13/
71)) and FRCpleth (16%(11/70)) remained virtually unchanged.
Signiﬁcant correlations were found between PFTs at 3 months
and 1 year (ﬁgure 2 and see online supplementary table E2). Of
the 52 infants in whom all three PFTs were technically success-
ful on both occasions, abnormalities were observed in 33% (17/
Figure 1 Success rates for recruitment and achievement of technically acceptable infant pulmonary function data. NBS, newborn screened; PFTs,
pulmonary function tests; LCI, lung clearance index; FRC, functional residual capacity; MBW, multiple breath inert gas washout; pleth,
plethysmographic technique; RVRTC,Raised Volume Rapid Thoraco-abdominal Compression, from which forced expired ﬂows and volumes were
derived. See online supplementary table E1 for details of PFT success on each test occasion.
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52) at ﬁrst test, 10 (59%) of whom remained abnormal at
follow-up. Of the 35 (67%) with entirely normal results at
3 months 25 (71%) remained so at 1-year.
Identiﬁcation of a high risk group of NBS CF infants
Based on results from LCI and FEV0.5 which were the most
feasible outcomes at 3 months (see online supplementary
table E1), we attempted to delineate a subgroup of infants who
would be at high risk of having abnormal lung function at
1 year, and who thus might be suitable candidates for an inter-
vention study. Among the 64 CF infants in whom acceptable
LCI and FEV0.5 results were obtained on both occasions, abnor-
malities (elevated LCI or diminished FEV0.5) were identiﬁed in
19 (30%) at ∼3 months, of whom 14 (74%) remained abnormal
at 1 year. Among CF infants with entirely normal PFTs at
3 months from these two tests (n=45), 36 (80%) remained so at
1 year (see online supplementary data for details). There were
no signiﬁcant differences at 1 year in FEV0.5 (−0.36 (−0.9 to
0.17) z-scores) or LCI (0.46 (−0.13 to 1.05) z-scores) between
CF infants with normal 3 months PFTs and healthy controls. By
contrast, when compared with controls at 1 year, LCI was 1.33
(0.6 to 2.1) z-scores higher and FEV0.5 −0.8 (−1.5 to −0.1)
z-scores lower in those with abnormal PFTs by 3 months (see
online supplementary table E3).
DISCUSSION
Contrary to our hypotheses, forced expired ﬂows and volumes
improved by 1 year of age, with stability of other PFTs in NBS
CF infants. This is the ﬁrst time such improvement has been
reported in an observational longitudinal study of NBS CF
infants. The number of CF infants with abnormal LCI and
FRCpleth at 1 year was similar to that at 3 months, while there
was a signiﬁcant reduction in those with abnormal FEV0.5
during this period. Impaired lung function at 1 year was pre-
dicted by lung function at 3 months and associated with
clinician-diagnosed wheeze (LCI), poor weight gain (LCI and
FRCpleth) and prior P aeruginosa (FRCpleth).
Strengths and limitations
The major strengths of this study are that longitudinal assess-
ments of lung function were undertaken in a large cohort of
NBS CF infants within a single location, results being directly
compared with healthy controls. Attrition was minimal,12 with
no bias between those who did and did not complete the study.
Selection of various PFTs enabled different aspects of patho-
physiology to be assessed.11 Appropriate reference equations for
infant PFTs,18 19 including LCI, which has now been shown to
be dependent on body size during early life,17 facilitated accur-
ate interpretation of results. Limitations are that, in an
Table 1 Characteristics of CF and healthy controls infants with paired lung function at 3 months and 1 year
CF (n=72) Controls (n=44) Δ (95% CI) CF– controls
Male, n (%) 34 (47) 21 (48) −1% (−19 to 18)
Gestational age, weeks 39.1 (1.4) 40.3 (1.1) −1.1 (−1.6 to −0.6)
Birth weight, z-score* −0.64 (0.84) 0.12 (0.81) −0.76 (−1.07 to −0.45)
Birth weight below 10th percentile*, n (%) 13 (18) 2 (5) 14% (1 to 24)
White mother, n (%) 61 (85) 38 (86) −2% (−14 to 13)
Maternal smoking during pregnancy, n (%) 8 (11) 3 (7) 4% (−8 to 15)
Current maternal smoking†, n (%) 9 (13) 5 (11) 1% (−13 to 13)
Maternal asthma, n (%) 14 (19) 8 (18) 1% (−14 to 15)
Cystic fibrosis infants only
Age at diagnosis, postnatal age (weeks) 3.9 (1.7)
CFTR genotype (classes I–III)‡ 59 (82%)
Presented with meconium ileus 7 (10%)
Pancreatic sufficient 5 (7%)
Respiratory symptoms ever prior to 1 year PFTs
Wheeze, physician diagnosed 24 (33%)
Crackles, physician diagnosed 6 (8%)
Cough within 3 weeks of 1-year PFT 15 (21%)
Bacterial growth on cough swab, ever§ prior to1 year PFTs
Pseudomonas aeruginosa, PsA¶ 25 (35%)
Other significant bacterial growth** 17 (24%)
No growth†† 30 (42%)
Additional treatment‡‡ prior to 1 year PFTs
rhDNase 6 (8%)
Intravenous antibiotics, number of courses 0 (0; 3)§§
GERD treatment 38 (53%)
Data shown as mean (SD) for continuous and n (%) for categorical variables unless otherwise stated.
*Calculated according to Cole et al.13
†Objectively validated by the analysis of cotinine levels.23
‡10% were classes IV–V and 8% unknown (or not classified).
§Swabs collected routinely in clinic at least every 2 months, prior to PFT and also when symptomatic.
¶Definition of colonisation according to Lee et al.24 Only 1 infant had chronic PsA.
**Significant bacterial infection with no previous PsA ever included 12 (17%) with methicillin-sensitive Staphylococcus Aureus, 14 (19%) with Haemophilus Influenzae, 3 (4%) with
Stenotrophomonas maltophilia, 2 (3%) with Achromobacter xylosidans, 3 (4%) with methicillin-resistant Staphylococcus Aureus and 2 (3%) with Aspergillus fumigatus.
††Included those with no growth, upper respiratory tract flora or isolated E Coli only.
‡‡In addition to the prophylactic flucloxacillin prescribed for all CF NBS infants from diagnosis.
§§Median (range).
Δ, mean difference between groups; CF, cystic fibrosis; GERD, Gastro-oesophageal reflux disease, n, number; NBS, newborn screened; PFT, pulmonary function test.
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Table 2 Comparison of anthropometry and pulmonary function at ∼3 months and 1 year in CF NBS infants and healthy controls (HC)
3 months 1 year Change over time (1 year–3 months)
CF (n=72) HC (n=44) CF−HC* CF (n=72) HC (n=44) CF−HC*
CF: Change 1 year
−3 months†
HC: Change 1 year
−3 months†
Difference in
change‡
CF−HC
Age at test, weeks§ 11.2 (2.3) 12.1 (2.1) −1.0 (−1.8 to −0.1) 52.4 (5.3) 53.7 (4.4) −1.3 (−3.1 to 0.5) 41.2 (37.3 to 43.1) 41.6 (38.6 to 43.6) −0.36 (−2.30 to 1.58)
Weight z-score¶ −0.89 (1.03) 0.01 (0.97) −0.90 (−1.27 to −0.52) 0.32 (0.90) 0.55 (1.21) −0.23 (−0.64 to 0.19) 1.21 (1.02 to 1.40) 0.54 (0.28 to 0.80) 0.67 (0.35 to 0.99)
Length z-score¶ −0.21 (1.01) 0.73 (0.92) −0.94 (−1.30 to −0.58) 0.47 (1.01) 0.76 (1.20) −0.28 (−0.71 to 0.15) 0.68 (0.52 to 0.85) 0.03 (−0.19 to 0.25) 0.66 (0.38 to 0.93)
BMI z-score¶ −1.08 (0.99) −0.55 (0.96) −0.53 (−0.90 to −0.16) 0.08 (0.83) 0.18 (1.12) −0.10 (−0.49 to 0.29) 1.15 (0.95 to 1.37) 0.72 (0.43 to 1.01) 0.44 (0.07 to 0.80)
LCI z-score 0.83 (1.32) 0.36 (0.85) 0.47 (0.06 to 0.87) 1.05 (1.23) 0.25 (0.95) 0.80 (0.40 to 1.21) 0.24 (−0.12 to 0.59) −0.09 (−0.46 to 0.28) 0.33 (−0.18 to 0.84)
FRCpleth z-score 0.75 (1.07) −0.01 (1.08) 0.77 (0.32 to 1.22) 0.75 (1.14) −0.05 (0.96) 0.80 (0.40 to 1.20) −0.04 (−0.32 to 0.23) −0.04 (−0.45 to 0.36) 0.00 (−0.48 to 0.49)
ΔFRC z-scores (pleth
− MBW)
0.59 (0.96) 0.22 (0.94) 0.37 (−0.32 to 0.77) 1.21 (0.86) 0.46 (0.69) 0.75 (0.44 to 1.06) 0.58 (0.26 to 0.89) 0.30 (−0.09 to 0.68) 0.28 (−0.21 to 0.77)
FVC z-score −0.50 (1.03) 0.23 (0.67) −0.74 (−1.06 to −0.41) −0.43 (1.16) 0.23 (0.94) −0.66 (−1.05 to −0.26) 0.06 (−0.18 to 0.29) −0.02 (−0.31 to 0.28) 0.08 (−0.29 to 0.45)
FEV0.5 z-score −1.23 (1.07) −0.16 (0.76) −1.07 (−1.42 to −0.73) −0.41 (1.03) 0.12 (0.92) −0.52 (−0.89 to −0.15) 0.83 (0.56 to 1.09) 0.24 (−0.07 to 0.56) 0.59 (0.18 to 0.99)
FEF75 z-score −0.76 (1.25) −0.07 (0.96) −0.69 (−1.11 to −0.27) −0.09 (0.93) 0.09 (0.91) −0.18 (−0.54 to 0.18) 0.84 (0.48 to 1.19) 0.20 (−0.17 to 0.58) 0.63 (0.12 to 1.14)
Data shown as mean (SD) or mean difference (95% CI) between: *Groups, †Test occasions.
‡Change over time between groups (CF- HC); significant differences (p <at least 0.05) are shown in bold.
§Corrected for gestational age.
¶Calculated according to Cole et al.13
BMI, Body Mass Index; CF, cystic fibrosis; FRCpleth, plethysmographic functional residual capacity; ΔFRC z-scores (pleth − MBW), difference between FRCpleth and FRCMBW z-scores as a measure of gas trapping; FVC, forced vital capacity; FEV0.5, forced
expired volume in 0.5 s; FEF75, forced expired flow when 75% of FVC has been expired; LCI, Lung Clearance Index; MBW, multiple breath inert gas washout; NBS, newborn screened.
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observational study such as this, we can only demonstrate associ-
ation not causation of potential determinants of 1 year lung
function. Computed tomography (CT) and broncho-alveolar
lavage were performed at 1 year in CF infants, but not at
3 months, and are therefore not reported in this paper, which
focusses on longitudinal changes. Furthermore, structural
changes on CT at 1 year were very mild and poorly
reproducible.25
Interpretation of PFTs
As reported previously,16 since the infant PFTs were selected to
reﬂect a wide a range of lung pathology, the relatively poor corre-
lations between the different primary outcomes on any one test
occasion (see online supplementary table E2) was not surprising.
While spirometry is known to be less sensitive than LCI for
detection of mild lung disease in preschool children with CF,8
during infancy FEV0.5 has been shown to be a sensitive outcome
in clinically diagnosed CF infants.16 While this was also observed
in this study of NBS infants at 3 months of age,11 by 1 year far
fewer NBS infants were identiﬁed by the raised volume technique
than either plethysmography or LCI. This may reﬂect the mild
nature of lung disease at 1 year in our NBS cohort when com-
pared with those diagnosed clinically and the decreasing sensitiv-
ity of forced expiratory manoeuvres to mild lung disease as
airway and chest-wall compliance decrease with increasing matur-
ity.26 By contrast with the lack of correlation between FEV0.5 and
other lung function outcomes on either test occasion, there were
signiﬁcant associations between LCI, FRCpleth and ΔFRC, all of
which are thought to be sensitive measures of peripheral airway
disease throughout childhood (see online supplementary table
E2). Whatever the interpretation of these changes, as discussed
below, they are in sharp contrast with those previously reported
in CF infants. Consequently, when selecting outcome measures
for intervention trials in NBS CF infants,27 reliance should not
be placed solely on the raised volume technique, since measures
of LCI appear essential if mild abnormalities are to be detected.
While hyperinﬂation and gas trapping also proved to be sensitive
outcomes at 1 year, routine inclusion of these outcomes shortly
after birth may be limited by equipment costs and increased
failure rate of FRCpleth in young infants. With the exception of a
signiﬁcantly lower FEV0.5 (mean (95% CI): −0.70 (−1.29 to
−0.10) z-scores) in those who received additional antibiotics for
symptoms or positive cough swab, there was no signiﬁcant associ-
ation between PFT outcomes and the infants’ genotype, clinical
status or any acute interventions prior to PFTs at 3 months.11
Comparison with the literature
Results regarding evolution of early lung disease in those diag-
nosed by NBS have been conﬂicting (ﬁgure 3). The Australian
Respiratory Early Surveillance team for CF (AREST-CF) have
reported normal and reduced PFTs in such infants within the ﬁrst
6 months of life,9 with further rapid deterioration over the ﬁrst
year of life (mean FEV0.5 being −2.4 z-scores by ∼1 year of age).10
In the current study, lung function was abnormal by
3 months,11 but stabilised or improved thereafter. As can be seen
from ﬁgure 3, 1 year-lung function in the LCFC NBS cohort was
signiﬁcantly better than that in previous clinically diagnosed
LCFC cohorts6 16 or in the AREST-CF NBS cohort at similar age.9
10 The reasons for the discrepancies between our results and those
for AREST-CF are unclear. While the standardised protocol
adhered to by the LCFC differs in some respects from that used by
most centres in the USA, Australia and Europe (eg, use of
Figure 2 Relationship between
pulmonary function at 3 months and
1 year in newborn screened CF infants.
The 95% limits of ‘normal range’
(97.5th centile for Lung Clearance
Index (LCI) and functional residual
capacity (FRC) and 2.5th centile for
FEV0.5) are represented by vertical
dashed lines at 3 months (3m) and
horizontal lines at 1 year (1yr). Those
with normal pulmonary function tests
on both occasions fall within the lower
left quadrant for LCI and FRC, and
upper right quadrant for FEV0.5. Infants
with abnormal LCI at 3 months but
normal LCI at a year, lie within the
lower right quadrant (A), while those
with abnormal FEV0.5 at 3 months
which has normalised by 1 year are
within the left upper quadrant of (C).
6 Nguyen TT-D, et al. Thorax 2013;0:1–8. doi:10.1136/thoraxjnl-2013-204023
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ﬂucloxacillin prophylaxis), the results should be a benchmark for
other centres, and could serve as the basis for quality improve-
ment.28 Median age at ﬁrst test in this study is younger than that
in AREST-CF, which may reﬂect earlier diagnosis and implementa-
tion of treatment within the narrow geographical area of southeast
England that we recruited from, thereby halting progression of
any early lung disease. It is possible that infants recruited to
AREST-CF were sicker, or deteriorated faster due to differences in
modiﬁer genes, environment or adherence to treatment, when
compared with those in London. Most importantly, by contrast
with the current study, AREST-CF data were not compared with
contemporaneous controls, historical controls being used initially,9
with subsequent results (obtained using higher inﬂation pres-
sures10) being interpreted using reference data based on different
equipment, which can bias interpretation.19 29
Improvements in lung function following treatment for acute
exacerbations in infants with CF have been demonstrated, 30 but
ours is the ﬁrst study to document improvements in FEV0.5 in
infants treated with standard therapy, studied during periods of
clinical stability. A recent exploratory study reported greater
increases in FEV0.5 over a 48-week period in 22 infants and
young children treated with hypertonic saline compared with 23
randomised to isotonic saline (mean (95% CI) difference:38
(1 to 76) mL).31 However, from the data presented, it is impos-
sible to ascertain whether this reﬂected stability, improvement
or simply less deterioration over time with active
treatment, once effects of lung and somatic growth had been
accounted for.
Clinical implications
These results have implications for clinical practice and research.
Although PFTs represent only one of the potential outcomes
that can be used during early life,27 with additional information
gleaned from inﬂammatory markers and computerised tomog-
raphy,32 they represent the mainstay of clinical management and
a major outcome in randomised controlled trials (RCTs) in chil-
dren and adults. Since lung function tracks from late infancy
into later life, accurate identiﬁcation of early abnormalities is
imperative. Furthermore, given the increasing number of centres
undertaking ‘clinical’ infant PFTs,33 the current study may facili-
tate more meaningful interpretation of results by providing vital
evidence regarding the natural changes that can occur over time
in healthy infants and those with lung disease, in the absence of
any speciﬁc interventions.
We have shown that lung function and somatic growth during
the ﬁrst year of life are signiﬁcantly better in infants diagnosed
by NBS in the UK than in their counterparts who were clinically
diagnosed a decade earlier6 16 (ﬁgure 3). It is, however, of
concern that despite early diagnosis and prompt treatment, LCI
remains abnormal at 1 year (ﬁgure 3), albeit to a mild degree.16
Further follow-up is required to establish the extent to which
these changes predict later outcome. Nevertheless, in this study,
normal lung function was sustained in at least 50% NBS CF
infants to 1 year of age. The signiﬁcant improvement in FEV0.5
and stability of sensitive measures of distal airway function
during early life when on ‘standard therapy’, and the relatively
small deﬁcits in lung function in CF NBS infants at 1 year also
have important implications for design of future randomised
intervention trials, which are essential to better deﬁne better
standards of care in this age group. Despite considerable within-
subject variability, the main predictor of lung function at 1 year
was that at 3 months, allowing us to identify a ‘high-risk’ group
who could potentially be targeted for future intervention trials.
Using data from this study, results from ∼85 infants/arm
would be required to detect relatively small differences in lung
function (ie, equivalent to 0.5 z-scores) that might occur in
response to an intervention if unselected NBS CF were recruited
to such a trial. By contrast, were recruitment to such a RCT
limited to a ‘high-risk group’ (ie, abnormal PFTs by 3 months,
see online supplementary tables E3 and E4), a larger treatment
effect would be expected, with only 22 infants/arm being
required to detect a difference of 1 z-score (equivalent to ∼9%
for LCI), with 90% power. Such an approach could optimise
recruitment since parents of infants with early PFT abnormal-
ities would be more likely to consent, and also this approach
would minimise exposure of children with potentially little to
gain from therapy from unnecessary side effects.
In summary, we have shown that some measures of pulmon-
ary function improve in the year following CF NBS diagnosis,
and none deteriorate. Performing randomised intervention
studies in an unselected cohort of infants using PFTs as an end
point will, therefore, require large sample sizes due to the gener-
ally mild changes in lung function observed. Nonetheless, it is
possible to identify CF infants with abnormal lung function by
3 months, who represent a high-risk group for persistent
Figure 3 Comparison of current lung function results in infants with
cystic ﬁbrosis (CF) and healthy controls (C) at ∼1 year of age, with
previously published results. Data expressed as mean (95% CI). To
allow direct comparison with previously published studies, Lung
Clearance Index is presented in absolute units, whereas FEV0.5 is
expressed as z-scores, based on different reference equations according
to each author. The dashed horizontal line at 0 z-scores equates to
100% predicted based on a healthy population. Control data were not
available in all studies. NBS, newborn screening.
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abnormalities at 1 year, and who may beneﬁt from additional
treatment during the vital ﬁrst few years of life.
Acknowledgements We thank the infants and parents who participated in this
study, and gratefully acknowledge contributions by all members of the London NBS
CF Collaboration (Ah-Fong Hoo, Ammani Prasad, Andrew Bush, Angie Wade, Anu
Shankar, Catherine Owen, Caroline Pao, Colin Wallis, Deeba Ahmed, Gary Ruiz,
Hilary Wyatt, Ian Balfour-Lynn, Jane Chudleigh, Jane Davies, Janet Stocks (Director),
John Price, Lena Thia, Lucy Brennan, Mark Rosenthal, Paul Aurora, Ranjan Suri,
Richard Chavasse, Siobhan Carr, Sooky Lum and The Thanh Diem Nguyen) and Per
Gustafsson for on-going advice and support with respect to MBW by Mass
spectrometry.
Contributors JS and AB were responsible for the conception and design of the
study; JS is responsible for supervision of the study and together with JC, for
research governance issues including ethics committee approval; A-FH provided
technical training, supervision and audit of data collection and analyses; A-FH and
JC set up the recruitment process. Infants with CF were recruited by the paediatric
respiratory consultants participating in the LCFC, including AB and PA. TT-DN, LPT,
A-FH, JC and SL recruited the healthy infants, undertook all lung function
measurements and, together with JS, calculated and interpreted lung function
results; TT-DN, LPT and AW performed statistical analyses; TT-DN, LPT, AB, PA and
JS drafted the manuscript; all remaining authors revised and approved the
manuscript for intellectual content before submission.
Funding This study is supported by grants from the Cystic Fibrosis Trust, UK;
Special Trustees: Great Ormond Street Hospital for Children, London, UK; Smiths
Medical Ltd, UK; Comprehensive Local Research Network, UK. It was also supported
by the NIHR Respiratory Disease Biomedical Research Unit at the Royal Brompton
and Hareﬁeld NHS Foundation Trust and Imperial College London.
Competing interests None.
Patient consent Obtained.
Ethics approval North Thames Multi-Centre Research Ethics Committee (#09/
HO71/314).
Provenance and peer review Not commissioned; externally peer reviewed.
Open Access This is an Open Access article distributed in accordance with the
Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which
permits others to distribute, remix, adapt, build upon this work non-commercially,
and license their derivative works on different terms, provided the original work is
properly cited and the use is non-commercial. See: http://creativecommons.org/
licenses/by-nc/3.0/
REFERENCES
1 Kerem E, Hirawat S, Armoni S, et al. Effectiveness of PTC124 treatment of cystic
ﬁbrosis caused by nonsense mutations: a prospective phase II trial. Lancet
2008;372:719–27.
2 Wilschanski M, Miller LL, Shoseyov D, et al. Chronic ataluren (PTC124) treatment of
nonsense mutation cystic ﬁbrosis. Eur Respir J 2011;38:59–69.
3 Ramsey BW, Davies J, McElvaney NG, et al. A CFTR potentiator in patients with
cystic ﬁbrosis and the G551D mutation. N Engl J Med 2011;365:1663–72.
4 Yu H, Burton B, Huang CJ, et al. Ivacaftor potentiation of multiple CFTR channels
with gating mutations. J Cyst Fibros 2012;11:237–45.
5 Ranganathan SC, Dezateux C, Bush A, et al. Airway function in infants newly
diagnosed with cystic ﬁbrosis. Lancet 2001;358:1964–5.
6 Ranganathan SC, Stocks J, Dezateux C, et al. The evolution of airway function in
early childhood following clinical diagnosis of cystic ﬁbrosis. Am J Respir Crit Care
Med 2004;169:928–33.
7 Kozlowska WJ, Bush A, Wade A, et al. Lung function from infancy to the preschool years
after clinical diagnosis of cystic ﬁbrosis. Am J Respir Crit Care Med 2008;178:42–9.
8 Aurora P, Stanojevic S, Wade A, et al. Lung clearance index at 4 years predicts
subsequent lung function in children with cystic ﬁbrosis. Am J Respir Crit Care Med
2011;183:752–8.
9 Linnane BM, Hall GL, Nolan G, et al. Lung function in infants with cystic
ﬁbrosis diagnosed by newborn screening. Am J Respir Crit Care Med
2008;178:1238–44.
10 Pillarisetti N, Williamson E, Linnane B, et al. Infection, inﬂammation, and lung
function decline in infants with cystic ﬁbrosis. Am J Respir Crit Care Med
2011;184:75–81.
11 Hoo AF, Thia LP, Nguyen TT, et al. Lung function is abnormal in 3-month-old
infants with cystic ﬁbrosis diagnosed by newborn screening. Thorax
2012;67:874–81.
12 Chudleigh J, Hoo AF, Ahmed D, et al. Positive parental attitudes to participating in
research involving newborn screened infants with CF. J Cyst Fibros
2012;12:234–40.
13 Cole TJ, Wright CM, Williams AF. Designing the new UK-WHO growth charts to
enhance assessment of growth around birth. Arch Dis Child Fetal Neonatal Ed
2012;97:F219–22.
14 Stocks J, Godfrey S, Beardsmore C, et al. Plethysmographic measurements of lung
volume and airway resistance. ERS/ATS Task Force on Standards for Infant
Respiratory Function Testing. European Respiratory Society/American Thoracic
Society. Eur Respir J 2001;17:302–12.
15 American Thoracic Society, European Respiratory Society statement: raised volume
forced expirations in infants: guidelines for current practice. Am J Respir Crit Care
Med 2005;172:1463–71.
16 Lum S, Gustafsson P, Ljungberg H, et al. Early detection of cystic ﬁbrosis lung
disease: multiple-breath washout versus raised volume tests. Thorax
2007;62:341–7.
17 Lum S, Stocks J, Stanojevic S, et al. Age and height dependence of lung clearance
index and functional residual capacity. Eur Respir J 2013;41:1371–7.
18 Nguyen TTD, Hoo AF, Lum S, et al. New reference equations to improve
interpretation of infant lung function . Pediatr Pulmonol 2013;48:370–80.
19 Lum S, Hoo AF, Hulskamp G, et al. Potential misinterpretation of infant lung
function unless prospective healthy controls are studied. Pediatr Pulmonol
2010;45:906–13.
20 Altman D, Machin D, Bryant TN, et al. Statistics with conﬁdence. 2nd edn. London:
BMJ Books, 2008:163–4.
21 Kirkwood BR, Sterne JAC. Essential Medical statistics. 2nd edn. New Jersey, NJ:
Wiley-Blackwell, 2008.
22 Petrie A, Sabin C. Medical statistics at a glance. 3rd edn. New Jersey, NJ:
Wiley-Blackwell, 2005:96–8.
23 Jarvis MJ, Fidler J, Mindell J, et al. Assessing smoking status in children,
adolescents and adults: cotinine cut-points revisited. Addiction 2008;103:1553–61.
24 Lee TW, Brownlee KG, Conway SP, et al. Evaluation of a new deﬁnition for chronic
Pseudomonas aeruginosa infection in cystic ﬁbrosis patients. J Cyst Fibros
2003;2:29–34.
25 Thia LP, Calder A, Owens CM, et al. Lung function and structure in CF infants
diagnosed through newborn screening [abstract]. J Cyst Fibros 2012;11(suppl 1):S15.
26 Lum S, Stocks J. Forced expiratory manoeuvres. In: Merkus P, Frey U.eds Paediatric
lung function. ERS Journals Ltd, 2010:46–65.
27 Stick S, Tiddens H, Aurora P, et al. Early intervention studies in infants and
preschool children with cystic ﬁbrosis: are we ready? EurRespir J 2013;42:527–538.
28 Quon BS, Goss CH. A story of success: continuous quality improvement in cystic
ﬁbrosis care in the USA. Thorax 2011;66:1106–8.
29 Stocks J, Modi N, Tepper R. Need for healthy control subjects when assessing lung
function in infants with respiratory disease. Am J Respir Crit Care Med
2010;182:1340–2.
30 Pittman JE, Johnson RC, Davis SD. Improvement in pulmonary function following
antibiotics in infants with cystic ﬁbrosis. Pediatr Pulmonol 2012;47:441–6.
31 Rosenfeld M, Ratjen F, Brumback L, et al. Inhaled hypertonic saline in infants and
children younger than 6 years with cystic ﬁbrosis: the ISIS randomized controlled
trial. JAMA 2012;307:2269–77.
32 Sly PD, Gangell CL, Chen L, et al. Risk factors for bronchiectasis in children with
cystic ﬁbrosis. N Engl J Med 2013;368:1963–70.
33 Peterson-Carmichael S, Rosenfeld M, Ascher SB, et al. Survey of clinical infant lung
function testing practices. Pediatr Pulmonol 2013 Published Online First: 13 June
2013. doi: 10.1002/ppul.22807
8 Nguyen TT-D, et al. Thorax 2013;0:1–8. doi:10.1136/thoraxjnl-2013-204023
Cystic ﬁbrosis
 group.bmj.com on September 3, 2014 - Published by thorax.bmj.comDownloaded from 
doi: 10.1136/thoraxjnl-2013-204023
 published online September 26, 2013Thorax
 
The Thanh-Diem Nguyen, Lena P Thia, Ah-Fong Hoo, et al.
 
fibrosis infants
year of life in newborn screened cystic 
Evolution of lung function during the first
 http://thorax.bmj.com/content/early/2013/09/26/thoraxjnl-2013-204023.full.html
Updated information and services can be found at: 
These include:
Data Supplement
 http://thorax.bmj.com/content/suppl/2013/09/26/thoraxjnl-2013-204023.DC1.html
"Supplementary Data"
References
 http://thorax.bmj.com/content/early/2013/09/26/thoraxjnl-2013-204023.full.html#ref-list-1
This article cites 28 articles, 7 of which can be accessed free at:
Open Access
non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/
terms, provided the original work is properly cited and the use is
work non-commercially, and license their derivative works on different 
license, which permits others to distribute, remix, adapt, build upon this
Creative Commons Attribution Non Commercial (CC BY-NC 3.0) 
This is an Open Access article distributed in accordance with the
P<P Published online September 26, 2013 in advance of the print journal.
service
Email alerting
the box at the top right corner of the online article.
Receive free email alerts when new articles cite this article. Sign up in
(DOIs) and date of initial publication. 
publication. Citations to Advance online articles must include the digital object identifier 
citable and establish publication priority; they are indexed by PubMed from initial
typeset, but have not not yet appeared in the paper journal. Advance online articles are 
Advance online articles have been peer reviewed, accepted for publication, edited and
 http://group.bmj.com/group/rights-licensing/permissions
To request permissions go to:
 http://journals.bmj.com/cgi/reprintform
To order reprints go to:
 http://group.bmj.com/subscribe/
To subscribe to BMJ go to:
 group.bmj.com on September 3, 2014 - Published by thorax.bmj.comDownloaded from 
Collections
Topic
 (1449 articles)Epidemiologic studies   
 (432 articles)Clinical trials (epidemiology)   
 (273 articles)Screening (public health)   
 (273 articles)Screening (epidemiology)   
 (426 articles)Cystic fibrosis   
 (119 articles)Open access   
 
Articles on similar topics can be found in the following collections
Notes
(DOIs) and date of initial publication. 
publication. Citations to Advance online articles must include the digital object identifier 
citable and establish publication priority; they are indexed by PubMed from initial
typeset, but have not not yet appeared in the paper journal. Advance online articles are 
Advance online articles have been peer reviewed, accepted for publication, edited and
 http://group.bmj.com/group/rights-licensing/permissions
To request permissions go to:
 http://journals.bmj.com/cgi/reprintform
To order reprints go to:
 http://group.bmj.com/subscribe/
To subscribe to BMJ go to:
 group.bmj.com on September 3, 2014 - Published by thorax.bmj.comDownloaded from 
